Vancouver is, as everyone knows, Canada's capital of illicit
intravenous drug use. Two years ago, the city's authorities
decided that further law enforcement wasn't the way to
tackle this problem. Instead they opted for a public health
based approach designed to minimize the harm associated
with injecting heroin and cocaine.
Even the once-recalcitrant police
have come to accept that safe injection facilities are
a practical way to reduce the harm done by drugs as
drug laws alone have utterly failed to curb rates of
use. The officer in charge of the drug enforcement branch
of the RCMP, Robert Lesser, said safe injection facillites
are "something we need to look at." Toronto's former
top cop, Julian Fantino, put it more bluntly when he
said: "Our jails are already filled with druggies. Fighting
drugs is like digging a hole in the Sahara desert."
POPULAR
ACCEPTANCE
When, in September 2003, Vancouver became the first
Canadian city to set up a safe injection facility, the
plan was supported by 71% of residents, according to
a poll reported in the Canadian Medical Association
Journal (CMAJ). And a CMAJ editorial argued
that "harm reduction is not a retreat from the high
ground. It is the only ground on which to meet drug
users in the here and now." Two years later, research
published online on March 18 in the Lancet reviews
the success of the city's safe injection facility and
finds that a tolerant approach to dealing with drug
users is paying dividends, as users of the facility
are far less likely to share needles.
The key finding reported in the
Lancet research letter is this: intravenous drug
users who frequented the facility for "some, most or
all" of their injections were only 30% as likely to
have shared a needle in the previous six months as injectors
who used the facility rarely or never, after adjustment
for other risk factors.
The other risk factors that influence
needle-sharing are age, older drug users being generally
less careful; binge drug-taking; and inability to self-inject
without another's help. All of these factors have been
found to increase the risk of sharing both in previous
studies and when the latest Vancouver data was broken
down.
CAN
WE TRUST THIS?
A potential weakness of the study is that drug users
who go to the injection facility are likely to be more
concerned about infection than those who do not, so
the lower rates of needle-sharing among the facility's
users could be due to their innately greater personal
responsibility. But the authors foresaw this problem,
so they questioned study participants on needle sharing
just before the facility opened. At this stage, the
injectors who later used the facility were as likely
to share needles as those who later stayed away. All
of the differences emerged after the needle-exchange
centre was opened.
In fact, according to lead author
Dr Thomas Kerr of the British Colombia Centre for Excellence
in HIV/AIDS, the facility's users tend to have more
risk factors for needle-sharing than the general injecting
population. "They are more likely to be homeless or
in unstable housing, and more likely to have been in
prison."
The 431-strong study population
is based on the Vancouver Injection Drug Users Study
(VIDUS). This isn't a random sample, concedes Dr Kerr.
"You could spend eternity trying to recruit a random
sample of drug users in Vancouver." But it has been
validated several times as a good representative sample.
Ninety of the 431 subjects reported frequent use of
the safe injection facility, but since the VIDUS cachement
area is larger than that served by the Downtown Eastside
facility, that figure probably under-represents the
proportion of local drug users who visit the site.
HOW
IT WORKS
The facility offers two services that can reduce needle-sharing.
One is the provision of clean needles and the disposal
of dirty ones. The other is the presence of supervising
nurses. "Basically," says Dr Kerr, "it's a large room
with 12 booths, each with a mirror that allows the nurses
to check on users." The nurses don't examine the drugs
before injection, but they are on hand in case there's
an overdose.
"The evidence suggests that the
needle-exchange aspect of the safe injection facility
is being used more and more," says Dr Kerr. Research
has shown that the great majority of Vancouver's intravenous
drug abusers make extensive use of the needle-exchange
program that the city has run since 1988, but it's had
little effect on infection rates. It still only takes
one dirty needle to ruin a life, particularly when 88%
of the VIDUS population has hepatitis C and 23% are
HIV-positive. "We've found that availability issues,
such as inadequate opening hours, have lessened the
effect of the program," he says. But users of the safe
injection facility are sure of clean needles at the
moment of injection.
The researchers might have proved
their point better by measuring actual infection rates
rather than self-reported needle-sharing, a sin that
even addicts are sometimes embarrassed to admit to.
But, said Dr Kerr, "the number of events is still too
small to get adequate statistical power from looking
at HIV or HCV infections. Needle-sharing is more than
a good surrogate measure, it's the actual cause of these
infections."
PROBLEMS
OFTEN OVERLOOKED
In fact, the most common cause of hospitalization among
injecting drug users in Canada is neither hepatitis
nor AIDS, but bacterial infections at the injection
site. "We will definitely be looking at bacterial infection
rates in future research," says Dr Kerr, "as well as
serious viral infections when we have enough data to
work with."
But the greatest potential benefit
of safe injection facilities could have nothing to do
with infection or needle-sharing, because even among
HIV-positive drug users in Canada, the leading killer
is not infection but overdose. And it goes without saying
that overdosing at a safe injection facility is a lot
less dangerous than overdosing in an apartment or a
back-alley. This effect, too, will be measured in later
research.
For the moment, Vancouver's facility
appears to have won over a lot of doubters. Its funding
was initially approved for three years, with extensions
subject to assessment of its early success. Dr Kerr
and his colleagues' research will probably help to guarantee
the centre's future, and lend support to those who want
to see such facilities in other Canadian cities. Efforts
to set up similar centres in Toronto and Montreal have
so far floundered in the face of concerted opposition
from neighbourhood associations.
Lancet published online Mar
18, 2005
|